A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Condition:   Multiple Sclerosis, Relapsing-Remitting Intervention:   Drug: Natalizumab Sponsor:   Biogen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials